Compare ACADIA Pharmaceuticals Inc. (ACAD) vs Nasdaq100 ETF (QQQ) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
ACADIA Pharmaceuticals Inc. vs Nasdaq100 ETF — how do they compare? ACADIA Pharmaceuticals Inc. trades at $29.45 (market cap $5.07B), while Nasdaq100 ETF trades at $722.47. The key difference: ACADIA Pharmaceuticals Inc. is trading nearer its 52-week high, Nasdaq100 ETF nearer its low. Which is the better fit depends on your goals.
| ACAD | QQQ | |
|---|---|---|
Market Cap | $5.07B | — |
Sector | Health | — |
52-Week High | $29.41 | $746.16 |
52-Week Low | $20.06 | $558.34 |
Enterprise Value | $4.19B | — |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
ACADIA Pharmaceuticals (ACAD) trades at $29.47, up 0.26% with strong technical momentum and bullish moving average signals. The company reported robust Q2 2026 earnings of $0.18 per share, beating estimates by 164%, driven by strong Daybue and Nuplazid sales. Revenue reached $1.07 billion in 2025 with impressive net income margins of 33.42%. Recent FDA Fast Track designation for remlifanserin in Alzheimer's disease psychosis adds to positive catalysts.
ACAD presents compelling growth potential with 70% analyst buy ratings and a $33.89 consensus price target implying 15% upside. Strong revenue growth trajectory and expanding profitability support bullish case, though elevated EV/EBITDA of 42.55 and recent RSI overbought signals warrant caution. Key risk remains clinical trial outcomes for pipeline assets.
QQQ trades at $723.65, up 0.39% today, with a bullish technical signal from moving averages and a neutral stance from oscillators. The ETF's momentum is supported by positive market breadth and tech earnings beats, though RSI levels suggest some near-term overbought conditions. A dividend of $0.81 per share is scheduled for July 2026.
Outlook remains positive given strong tech sector performance and institutional inflows, but risks include high valuation sensitivity and market volatility. Analyst sentiment is split evenly between buy and sell recommendations, reflecting uncertainty over sustained growth versus potential pullbacks.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About ACADIA Pharmaceuticals Inc.
Acadia Pharmaceuticals is a biotechnology company that develops and commercializes biopharmaceutical products to address central nervous system disorders. The company aims to discover small molecule drugs that address disorders such as Parkinson's, Alzheimer's, and schizophrenia. Acadia also seeks to in-license or acquire complementary products and candidates. The company's patent applications claim proprietary technology, including novel methods of screening and chemical synthetic methods, novel drug targets, and novel compounds identified using its technology.
Read more on ACAD →About Nasdaq100 ETF
The ETF is designed to track the performance of the securities and the stocks in the NASDAQ-100 Index. To maintain the composition and weightings, the advisor adjusts the ETF from time to time to conform to periodic changes in the index target.
Read more on QQQ →
